Migraine is a common disabling disease but its economic burden has not been adequately quantified.
To estimate the burden of migraine in the United States with respect to disability and economic costs.
The following data sources were used : published data, the Baltimore County Migraine Study, MEDSTAT's MarketScan medical claims data set, and statistics from the Census Bureau and the Bureau of Labor Statistics.
Disability was expressed as bedridden days.
Charges for migraine-related treatment were used as direct cost inputs.
The human capital approach was used in the estimation of indirect costs.
Migraineurs required 3.8 bed rest days for men and 5.6 days for women each year, resulting in a total of 112 million bedridden days.
Migraine costs American employers about $13 billion a year because of missed workdays and impaired work function ; close to $8 billion was directly due to missed workdays.
Patients of both sexes aged 30 to 49 years incurred higher indirect costs compared with younger or older employed patients.
Annual direct medical costs for migraine care were about $1 billion and about $100 was spent per diagnosed patient.
Physician office visits accounted for about 60% of all costs ; in contrast, emergency department visits contributed less than 1% of the direct costs.
The economic burden of migraine predominantly falls on patients and their employers in the form of bedridden days and lost productivity. (...)
Mots-clés Pascal : Migraine, Dépistage, Prévalence, Incapacité, Etude longitudinale, Facteur risque, Analyse coût, Base donnée, Evaluation, Etats Unis, Amérique du Nord, Amérique, Homme, Douleur, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Cérébrovasculaire pathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Economie santé
Mots-clés Pascal anglais : Migraine, Medical screening, Prevalence, Disability, Follow up study, Risk factor, Cost analysis, Database, Evaluation, United States, North America, America, Human, Pain, Nervous system diseases, Central nervous system disease, Cerebral disorder, Cerebrovascular disease, Cardiovascular disease, Vascular disease, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0269915
Code Inist : 002B17A03. Création : 16/11/1999.